Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 1NETWORK 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

enzalutamide 2darolutamide 1apalutamide 1abiraterone 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Hormone-sensitive Prostate Cancer × 1 year × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡